|1.||Anderson, Kenneth C: 56 articles (12/2015 - 02/2002)|
|2.||Richardson, Paul G: 44 articles (01/2016 - 06/2002)|
|3.||Dimopoulos, Meletios A: 31 articles (10/2015 - 01/2002)|
|4.||Rajkumar, S Vincent: 31 articles (01/2015 - 11/2002)|
|5.||Moreau, Philippe: 30 articles (01/2016 - 11/2006)|
|6.||Facon, Thierry: 25 articles (12/2015 - 06/2005)|
|7.||van de Beek, Diederik: 25 articles (10/2015 - 11/2002)|
|8.||Sonneveld, Pieter: 25 articles (09/2015 - 03/2003)|
|9.||Palumbo, Antonio: 25 articles (09/2015 - 01/2004)|
|10.||Niesvizky, Ruben: 24 articles (12/2015 - 03/2002)|
04/01/2008 - "A significant reduction in vomiting from 27% to 11% was achieved following the introduction of routine use of intravenous dexamethasone during surgery. "
04/01/2003 - "Compared with placebo, dexamethasone significantly decreased the incidence of early and late vomiting (P < 0.05, P < 0.001 respectively). "
02/01/1995 - "Addition of dexamethasone significantly improved prevention of both acute and delayed emesis. "
01/01/1998 - "Six patients in group D and 19 in group S experienced vomiting at least once within the 24-h postoperative period; dexamethasone was effective in reducing the overall incidence of vomiting from 63.3% to 20.0% (P < 0.01). "
10/01/2000 - "Dexamethasone is clearly effective in protecting from emesis both in the acute and delayed phases, with emesis avoided in one patient out of six treated. "
01/01/2016 - "Recent studies showed that CAM was highly effective against multiple myeloma (MM) when used in combination with immunomodulatory drugs and dexamethasone. "
01/01/1998 - "The authors describe a case of multiple myeloma in which a complete remission was obtained by treatment with high dose dexamethasone. "
10/01/2009 - "The high-dose dexamethasone-based regiments are safe and effective for newly diagnosed multiple myeloma patients with renal impairment."
02/01/1999 - "The use of biological modifiers in combination with dexamethasone offer a safe and effective therapeutic option in patients with refractory multiple myeloma. "
06/01/2015 - "In the present study, we conducted a subgroup analysis of the MM-021 registration trial to investigate the efficacy and safety of LEN plus low-dose dexamethasone (LoDEX) in Chinese patients with advanced relapsed or refractory multiple myeloma (RRMM) based on levels of RI. "
|3.||Postoperative Nausea and Vomiting (PONV)
02/01/2001 - "Of them, dexamethasone used as a prophylactic drug for PONV provided the best results. "
01/01/2008 - "Dexamethasone has been proven effective in the prophylaxis of late PONV. "
01/01/2014 - "Dexamethasone 8-10mg had a significantly greater effect for reducing the incidence of PONV than dexamethasone 1.25-5mg. "
08/01/2007 - "A single dose of dexamethasone significantly decreased the incidence of postoperative vomiting in early and late recovery phase and shortened the time to first oral intake and the duration of IV therapy."
03/01/2001 - "Dexamethasone significantly decreased the incidence of postoperative vomiting during the first 24 h, shortened the time to the first oral intake and the duration of IV hydration, and improved the quality of oral intake and the satisfaction scores of the patients."
04/01/2015 - "Patients at risk for post-operative nausea are treated with anti-emetic medications and perioperative dexamethasone. "
03/01/2013 - "During the first 24 hours, nausea occurred in 12/35 (34.4%) patients receiving dexamethasone and in 32/35 (91.4%) receiving placebo (P<0.001). "
01/01/2009 - "Seven patients (18%) in the dexamethasone group reported nausea, compared with 16 (40%) in the placebo group (p = 0.026). "
04/01/2008 - "Seven patients in the control group, but only one in the dexamethasone group, were treated for nausea (P = 0.05). "
04/01/2007 - "Average nausea scores were low in all groups, but the incidence of nausea until 24 h postoperatively was significantly higher among groups receiving only 2 mg of dexamethasone (P < 0.03). "
09/01/2015 - "The application of 0.4% dexamethasone iontophoresis and the use of Cyriax-type exercises both provided significant improvement in the pain, patient's satisfaction, and the power of the handgrip, and there were no significant difference (p > 0.001) in any of the three measures after the first week's treatment. "
07/01/2015 - "In patients with LBPR, a single dose of intravenous dexamethasone in addition to routine management improved VAS pain scores at 24 h, but this effect was not statistically significant at 6 weeks. "
11/01/2011 - "Transforaminal epidural dexamethasone provides statistically significant and clinically meaningful improvement in radicular pain at 12 weeks after injection, with parallel improvements in disability, impression of change, and satisfaction measures. "
09/01/2011 - "Both dexamethasone groups showed a significant reduction in swelling and pain compared with the control group at all intervals (P < .05). "
07/01/2011 - "Dexamethasone group showed significant reduction in pain and swelling postoperatively compared with the control. "
|8.||lenalidomide (CC 5013)
|1.||Drug Therapy (Chemotherapy)
|4.||Stem Cell Transplantation